Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer - Seite 2
About uPath image analysis algorithm suite
The uPath image analysis algorithm suite for pathology decision support offers ready-to-use image analysis tools, providing fast, consistent and automated analysis so that pathologists can quickly,
accurately and confidently assess immunohistochemistry and in situ hybridization. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images
stained with a Roche Tissue Diagnostics assay. Together, Roche is delivering a new foundation of its digital pathology solution which will enable the development of artificial intelligence-based
image analysis algorithms that can provide pathologists more tools to improve efficiency and precision.
Roche is delivering the end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms. Roche minimizes the variables that can impact analysis, and it is this end-to-end development that produces the quality results customers can depend on for making clinical decisions. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented tools into routine clinical practice.
Lesen Sie auch
About breast cancer
Breast cancer is the second most common cancer in the world, with an estimated 1.7 million new cancer cases diagnosed in 2012 (25% of all cancers). It is the most common cancer in women globally.
Incidence rates vary nearly four-fold across the world regions, with rates ranging from 27 per 100,000 in Africa and Asia to 92 per 100,000 in North America.1,2
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and
diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is
also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to
medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among
them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the
Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).